查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529797

糖尿病神經病變管理市場規模、佔有率、趨勢分析報告：按設備、應用、最終用途、地區和細分市場預測，2024-2030 年

Diabetic Neuropathy Management Market Size, Share & Trends Analysis Report By Devices (Electrical stimulation, Neuro Stimulation Devices), By Application (Peripheral Neuropathy), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 220 Pages | 商品交期: 2-10個工作天內

價格

市場規模及趨勢

2023年，糖尿病神經病變治療的全球市場規模估計為26.2億美元，預計2024年至2030年複合年成長率為5.8%。推動市場成長的主要因素包括糖尿病盛行率增加、老年人口增加、技術進步、研發活動增加以及產品核可數量增加。根據美國疾病管制與預防中心（CDC）的統計，大約有11.6%的美國，即3840萬美國患有糖尿病，估計其中一半人在一生中的某個時刻會患上糖尿病性神經病變。是。

糖尿病的高盛行率是推動市場成長的主要因素。如果不加以控制，糖尿病會導致各種嚴重的併發症，包括周邊神經病變。根據國際糖尿病聯盟 (IDF) 的數據，2021 年全球有 5.37 億成年人患有糖尿病，預計到 2040 年這一數字將躍升至 6.42 億。糖尿病的盛行率在全球範圍內不斷增加，尤其是在低收入和中等收入國家。 2021 年，西太平洋、南亞和歐洲的成人糖尿病患者人數將最多，分別為 1.67 億、8,800 萬和 5,900 萬人。

此外，更容易患糖尿病神經病變的老年人數量顯著增加。由於長期糖尿病、神經再生能力下降以及加劇神經病變症狀的合併症等因素，老年人口尤其容易受到影響。隨著世界人口老化，世界衛生組織（WHO）預測，到2030年，60歲以上的人口數量將增加到六分之一，從2020年的10億增加到最近的14億。到2050年，全球60歲及以上人口預計將增加一倍，達到21億，80歲以上人口預計將增加兩倍，達到4.26億。這些人口變化預計將增加糖尿病和周邊神經病變等慢性疾病的可能性，從而增加老年人糖尿病神經病變的風險。

糖尿病神經病變管理市場的成長是由各種腦部影像技術的使用所推動的，例如電刺激設備、神經刺激設備和神經傳導測試設備，這些技術為功能性神經病變、周邊神經病變和自主神經病變。此外，製造商在關鍵應用領域爭奪技術進步和產品核可正在推動市場向前發展。 2023 年 10 月，波士頓科學公司宣布用於治療疼痛性糖尿病周邊神經病變(PDN) 的脊髓刺激設備脊髓刺激設備Wavelighter Alpha 脊髓刺激器 (SCS) 已獲得核准，PDN 是併發症。這一擴大的適應症使波士頓科學公司在不斷成長的 PDN 市場上與雅培 (Abbott)、美敦力(Medtronic) 和 Nebro 競爭。

「使用 SCS 來支持一部分糖尿病患者是世界上成長最快的慢性疾病之一的重要進步。

這種擴大的適應症再次證明了我們致力於提供強大的介入性疼痛解決方案組合的承諾，為醫生提供更多的治療選擇，以減輕患者的疼痛。 」

吉姆‧卡西迪 (Jim Cassidy)，波士頓科學公司神經調節部總裁。

政府和私人組織為提高意識和治療神經病變而採取的幾項措施預計將有助於市場成長。例如，2022 年 5 月，Averitas Pharma 在美國進行了 PDPN 疾病宣傳活動，旨在提高人們對患有疼痛的糖尿病周邊神經病變(PDPN) 患者的重大未滿足醫療需求的認知。該宣傳活動將包括患者調查、教育材料和媒體參觀，以提高對該疾病的認知並鼓勵患者接受適當的治療。

「這項獨特的比賽旨在了解患者如何表達糖尿病足神經疼痛。

透過用患者自己的話重新定義症狀，糖尿病周邊神經神經病變患者和他們的醫療保健提供者可以使用通用的語言來討論症狀，改善診斷、疾病管理和潛在的解決方案，目標是促進圍繞政策的更富有成效的對話。 」

Lizandra Marcondes 博士，Averitas Pharma 醫療事務主管。

醫療技術的創新大大改善了糖尿病神經病變的診斷、監測和治療。從能夠早期檢測的先進診斷影像技術到新的藥物傳輸系統和神經調節療法，這些技術突破正在重塑神經病變管理的模式。此外，電神經刺激設備與遠端醫療和遠端監控解決方案的整合正在改善獲得專業護理的機會，特別是對於農村和服務欠缺地區的患者。例如，2022年7月，FDA批准了DyAnsys的First Relief經皮神經電刺激（PENS）裝置，用於治療糖尿病周邊神經病變引起的慢性、頑固性疼痛。該設備提供連續的低電平電流脈衝，並放置在耳後。這項核准基於臨床研究，該研究表明使用 First Relief 的患者可顯著降低疼痛強度並改善振動感知、失眠和焦慮等次要終點。該裝置為患有與糖尿病周邊神經病變相關的神經病變疼痛的患者提供了非藥物、非麻醉性治療選擇。

我們很高興 FDA 批准了 First Relief，使我們能夠使用這種經過驗證的設備來治療與糖尿病神經病變相關的疼痛患者。

First Relief 提供不涉及藥物或麻醉劑的重要治療選擇。 」

DyAnsys 執行長 Srini Nageshwar。

糖尿病神經病變日益增加的經濟負擔導致該領域的醫療保健支出增加。政府和醫療機構正在分配更多資源來有效管理這種疾病，並認知到早期療育和綜合護理的長期成本效益。使用人工智慧開發非侵入性診斷工具將增強早期發現並帶來更及時、更有效的治療。 2023 年 10 月，加州大學聖地牙哥分校 (UCSD) 的研究人員獲得了 360 萬美元的津貼，用於開發一種新的糖尿病神經病變診斷和治療組合。該計劃旨在建立一種整合先進診斷工具和標靶治療的綜合方法。此外，隨著新藥、設備和治療方法的核准不斷增加，糖尿病神經病變管理的監管環境也不斷發展。

糖尿病神經病變管理全球市場報告細分

該報告預測了全球、區域和國家層面的收益成長，並對2018年至2030年各子區隔的最新行業趨勢進行了分析。在這項研究中，Grand View Research 根據設備、應用、最終用途和區域對全球糖尿病神經病變管理市場報告進行了細分：

  • 設備展望（銷售，2018-2030 年）。
  • 電刺激設備。
  • 神經刺激設備。
  • 神經傳導測試設備。
  • 其他設備。
  • 應用前景（銷量，2018-2030）。
  • 周邊神經病變。
  • 自主神經病變。
  • 近端神經病變。
  • 單神經炎。
  • 最終用途展望（收益，百萬美元，2018-2030 年）。
  • 醫院。
  • 家庭保健。
  • 其他最終用途。
  • 區域展望（收入，2018-2030）。
  • 北美。

美國。

加拿大

墨西哥

  • 歐洲

英國

德國

法國

義大利

西班牙

丹麥

瑞典

挪威

  • 亞太地區

日本

中國

印度

澳洲

泰國

韓國

  • 拉丁美洲

巴西

阿根廷

  • 中東和非洲

南非

沙烏地阿拉伯

阿拉伯聯合大公國

科威特

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章糖尿病神經病變管理市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 糖尿病神經病變管理市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第 4 章 糖尿病神經病變管理市場：設備評估與趨勢分析

  • 細分儀表板
  • 全球糖尿病神經病變治療器材市場波動分析
  • 2018-2030 年全球糖尿病神經病變治療市場規模與趨勢分析（按設備）
  • 電刺激設備
  • 神經刺激設備
  • 神經傳導測試儀
  • 其他設備

第5章糖尿病神經病變管理市場：應用估計與趨勢分析

  • 細分儀表板
  • 全球糖尿病神經病變管理應用市場波動分析
  • 2018-2030 年全球糖尿病神經病變管理市場規模及趨勢分析（按應用）
  • 周邊神經病變
  • 自主神經病變
  • 近端神經病變
  • 神經病變（局部神經病變）

第6章糖尿病神經病變管理市場：最終用途估計與趨勢分析

  • 細分儀表板
  • 全球糖尿病神經病變管理最終用途市場波動分析
  • 2018-2030 年全球糖尿病神經病變管理市場規模與趨勢分析（依最終用途）
  • 醫院
  • 家庭保健
  • 其他最終用戶

第7章糖尿病神經病變管理市場：按設備、應用和最終用途進行的區域估計和趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概述
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 2023年主要企業市場佔有率分析
  • Company Position Analysis
  • 公司分類（新興企業、創新企業、領導者）
  • 公司簡介
    • Medtronic
    • NEVRO CORP.
    • NeuroMetrix, Inc.
    • Abbott
    • Boston Scientific Corporation
    • Neuralace
    • Fremslife SrlPI
    • DyAnsys Inc.
    • IMPETO MEDICAL
Product Code: GVR-4-68040-361-8

Market Size & Trends

The global diabetic neuropathy management market size was estimated at USD 2.62 billion in 2023 and is expected to grow at a CAGR of 5.8% from 2024 to 2030. Major factors contributing to the market growth include the growing prevalence of diabetes, the rising geriatric population, technological advancements, increased in R&D activities, and the increase in number of product approvals. According to Centers for Disease Control and Prevention (CDC) statistics, approximately 11.6% of the U.S. population, or 38.4 million Americans, live with diabetes and are estimated that half of these individuals are likely to develop diabetic neuropathy at some point during their lifetime.

High prevalence of diabetes is the major factor driving the market growth. Diabetes, when left unmanaged, can lead to a range of serious complications, including peripheral neuropathy. According to the International Diabetes Federation (IDF), 537 million adults worldwide lived with diabetes in 2021, it further states that the number is expected to surge to 642 million by 2040. The prevalence of diabetes is increasing globally, with the most significant rises observed in low- and middle-income countries. The Western Pacific, South Asia, and Europe had the highest numbers of adults living with diabetes in 2021, at 167 million, 88 million, and 59 million respectively.

Furthermore, there is a notable increase in the number of elderly individuals prone to developing diabetic neuropathy. The geriatric population is particularly vulnerable due to factors such as longer diabetes duration, decreased nerve regeneration capacity, and comorbidities that can exacerbate neuropathic symptoms. As the global population ages, the World Health Organization (WHO) predicts that the number of people aged 60 years and older will increase to 1 in 6 by 2030, rising from 1 billion in 2020 to 1.4 billion recently. The global population of people aged 60 years, and older is expected to double to 2.1 billion by 2050, with individuals aged 80 years or older set to triple to 426 million. This demographic shift is expected to lead to a higher chances of chronic conditions like diabetes and peripheral neuropathy, increasing the risk of diabetic neuropathy among seniors.

The diabetic neuropathy management market growth is anticipated to be driven by the availability of various brain imaging technologies, including electrical stimulation devices, neuro stimulation devices, nerve conduction testing devices, which offer applications for both functional and peripheral neuropathy and autonomic neuropathy. Additionally, technological advancements and manufacturers competing for product approval in key application areas drive the market forwards. In October 2023, Boston Scientific received FDA approval for its spinal cord stimulation device WaveWriter Alpha Spinal Cord Stimulator (SCS) to treat painful diabetic peripheral neuropathy (PDN), a complication of diabetes affecting the legs and feet. This expanded indication positions Boston Scientific to compete with Abbott, Medtronic and Nevro in the growing PDN market.

"The use of SCS to support a subset of the diabetes population is an important advancement for one of the fastest growing chronic conditions in the world.

This expanded indication is another testament to our commitment to delivering a robust portfolio of interventional pain solutions that provides physicians with more treatment choices to help their patients find relief."

Jim Cassidy, president of Neuromodulation at Boston Scientific.

Several initiatives undertaken by the government and private organizations for the awareness and treatment of neuropathy are expected to contribute to market growth. For instance, in May 2022, the US PDPN Disease Awareness Campaign, conducted by Averitas Pharma, aims to raise awareness about the significant unmet medical needs of patients with painful diabetic peripheral neuropathy (PDPN). This campaign involves patient-focused surveys, educational materials, and media tours to increase disease awareness and encourage patients to seek appropriate treatment.

"We launched this unique contest in the community to better understand how patients describe diabetic nerve pain of their feet in their own terms.

By redefining the symptoms using their own words, our goal is to help diabetic peripheral neuropathy patients and their health care providers start using common language to talk about their symptoms, fostering more productive conversations around diagnosis, disease management and potential solutions."

Dr. Lizandra Marcondes, Head Medical Affairs Averitas Pharma.

Innovations in medical technology have significantly improved the diagnosis, monitoring, and treatment of diabetic neuropathy. From advanced imaging techniques that allow for early detection to novel drug delivery systems and neuromodulation therapies, these technological breakthroughs are reshaping the landscape of neuropathy management. Additionally, the integration of telemedicine and remote monitoring solutions and electrical neurostimulation devices has enhanced access to specialized care, particularly for patients in rural or underserved areas. For instance, July 2022, the FDA cleared the First Relief percutaneous electrical neurostimulation (PENS) device by DyAnsys for the treatment of chronic, intractable pain from diabetic peripheral neuropathy. The device delivers continuous pulses of low-level electrical current and is placed behind the ear. The approval was based on a clinical study that showed patients treated with First Relief experienced a significant reduction in pain intensity, as well as improvements in secondary endpoints like vibration perception, insomnia, and anxiety. The device offers a non-drug, non-narcotic treatment option for patients suffering from neuropathic pain associated with diabetic peripheral neuropathy.

''We are excited to have the FDA clearance of First Relief so that this device, which has been proven effective, can now be used to treat patients who have been experiencing pain related to diabetic neuropathy.

First Relief offers a significant treatment option without drugs or narcotics."

DyAnsys CEO Srini Nageshwar.

The growing economic burden of diabetic neuropathy has led to increased healthcare spending in this area. Governments and healthcare organizations are allocating more resources to manage this condition effectively, recognizing the long-term cost benefits of early intervention and comprehensive care. The development of non-invasive diagnostic tools using AI will enhance early detection, leading to more timely and effective treatments. In October 2023, researchers at the University of California, San Diego (UCSD) have received a grant of USD3.6 million to develop a novel combination of diagnosis and treatment for diabetic neuropathy. This project aims to create a comprehensive approach that integrates advanced diagnostic tools with targeted therapies. Further the regulatory landscape for diabetic neuropathy management is evolving, with an uptick in the approval of new drugs, devices, and treatment modalities.

Global Diabetic Neuropathy Management Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global diabetic neuropathy management market report based on devices, application, end-use, and region:

  • Devices Outlook (Revenue, USD Million, 2018 - 2030)
  • Electrical Stimulation Devices
  • Neuro Stimulation Devices
  • Nerve Conduction Testing Devices
  • Other Devices
  • Application Outlook (Revenue, USD Million, 2018 - 2030)
  • Peripheral Neuropathy
  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Mononeuropathy
  • End-use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospitals
  • Home Healthcare
  • Other End-use
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America

U.S.

Canada

Mexico

  • Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

  • Asia Pacific

Japan

China

India

Australia

Thailand

South Korea

  • Latin America

Brazil

Argentina

  • Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Device
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Device outlook
    • 2.2.2. Application outlook
    • 2.2.3. Modality outlook
    • 2.2.4. End use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Diabetic Neuropathy Management Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. High prevalence of diabetes and associated disorders
      • 3.2.1.2. Technological advancements
      • 3.2.1.3. Increase in R&D activities
      • 3.2.1.4. Increasing healthcare expenditure
      • 3.2.1.5. Untapped opportunities in developing economies
      • 3.2.1.6. Increase in number of product approvals
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High-cost barrier
      • 3.2.2.2. Lack of skilled professionals
      • 3.2.2.3. Stringent regulatory approvals
  • 3.3. Diabetic Neuropathy Management Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Diabetic Neuropathy Management Market: Device Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Diabetic Neuropathy Management Device Market Movement Analysis
  • 4.3. Global Diabetic Neuropathy Management Market Size & Trend Analysis, by Device, 2018 to 2030 (USD Million)
  • 4.4. Electrical Stimulation Devices
    • 4.4.1. Electrical stimulation devices market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Neuro Stimulation Devices
    • 4.5.1. Neuro stimulation devices market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Nerve Conduction Testing Devices
    • 4.6.1. Nerve conduction testing devices market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Other Devices
    • 4.7.1. Other devices market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Diabetic Neuropathy Management Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Diabetic Neuropathy Management Application Market Movement Analysis
  • 5.3. Global Diabetic Neuropathy Management Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Peripheral Neuropathy
    • 5.4.1. Peripheral neuropathy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Autonomic Neuropathy
    • 5.5.1. Autonomic neuropathy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Proximal Neuropathy
    • 5.6.1. Proximal neuropathy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Mononeuropathy (focal neuropathy)
    • 5.7.1. Mononeuropathy (focal neuropathy) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Diabetic Neuropathy Management Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Diabetic Neuropathy Management End Use Market Movement Analysis
  • 6.3. Global Diabetic Neuropathy Management Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Home Healthcare
    • 6.5.1. Diagnostic imaging centers market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Other End Users
    • 6.6.1. Others end users market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Diabetic Neuropathy Management Market: Regional Estimates & Trend Analysis By Devices, Application, End Use

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Competitive scenario
      • 7.5.1.3. Regulatory framework
      • 7.5.1.4. Reimbursement structure
      • 7.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Reimbursement structure
      • 7.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. Reimbursement structure
      • 7.5.3.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Competitive scenario
      • 7.6.1.3. Regulatory framework
      • 7.6.1.4. Reimbursement structure
      • 7.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Reimbursement structure
      • 7.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Reimbursement structure
      • 7.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Competitive scenario
      • 7.6.4.3. Regulatory framework
      • 7.6.4.4. Reimbursement structure
      • 7.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Competitive scenario
      • 7.6.5.3. Regulatory framework
      • 7.6.5.4. Reimbursement structure
      • 7.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Competitive scenario
      • 7.6.6.3. Regulatory framework
      • 7.6.6.4. Reimbursement structure
      • 7.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Competitive scenario
      • 7.6.7.3. Regulatory framework
      • 7.6.7.4. Reimbursement structure
      • 7.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Competitive scenario
      • 7.6.8.3. Regulatory framework
      • 7.6.8.4. Reimbursement structure
      • 7.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Competitive scenario
      • 7.7.1.3. Regulatory framework
      • 7.7.1.4. Reimbursement structure
      • 7.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Reimbursement structure
      • 7.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Reimbursement structure
      • 7.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. Reimbursement structure
      • 7.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Competitive scenario
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Reimbursement structure
      • 7.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Competitive scenario
      • 7.7.6.3. Regulatory framework
      • 7.7.6.4. Reimbursement structure
      • 7.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Competitive scenario
      • 7.8.1.3. Regulatory framework
      • 7.8.1.4. Reimbursement structure
      • 7.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Competitive scenario
      • 7.8.2.3. Regulatory framework
      • 7.8.2.4. Reimbursement structure
      • 7.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Competitive scenario
      • 7.9.1.3. Regulatory framework
      • 7.9.1.4. Reimbursement structure
      • 7.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Competitive scenario
      • 7.9.2.3. Regulatory framework
      • 7.9.2.4. Reimbursement structure
      • 7.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Competitive scenario
      • 7.9.3.3. Regulatory framework
      • 7.9.3.4. Reimbursement structure
      • 7.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Competitive scenario
      • 7.9.4.3. Regulatory framework
      • 7.9.4.4. Reimbursement structure
      • 7.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Key company market share analysis, 2023
  • 8.4. Company Position Analysis
  • 8.5. Company Categorization (Emerging Players, Innovators and Leaders
  • 8.6. Company Profiles
    • 8.6.1. Medtronic
      • 8.6.1.1. Company overview
      • 8.6.1.2. Financial performance
      • 8.6.1.3. Device benchmarking
      • 8.6.1.4. Strategic initiatives
    • 8.6.2. NEVRO CORP.
      • 8.6.2.1. Company overview
      • 8.6.2.2. Financial performance
      • 8.6.2.3. Device benchmarking
      • 8.6.2.4. Strategic initiatives
    • 8.6.3. NeuroMetrix, Inc.
      • 8.6.3.1. Company overview
      • 8.6.3.2. Financial performance
      • 8.6.3.3. Device benchmarking
      • 8.6.3.4. Strategic initiatives
    • 8.6.4. Abbott
      • 8.6.4.1. Company overview
      • 8.6.4.2. Financial performance
      • 8.6.4.3. Device benchmarking
      • 8.6.4.4. Strategic initiatives
    • 8.6.5. Boston Scientific Corporation
      • 8.6.5.1. Company overview
      • 8.6.5.2. Financial performance
      • 8.6.5.3. Device benchmarking
      • 8.6.5.4. Strategic initiatives
    • 8.6.6. Neuralace
      • 8.6.6.1. Company overview
      • 8.6.6.2. Financial performance
      • 8.6.6.3. Device benchmarking
      • 8.6.6.4. Strategic initiatives
    • 8.6.7. Fremslife S.r.l. P.I.
      • 8.6.7.1. Company overview
      • 8.6.7.2. Financial performance
      • 8.6.7.3. Device benchmarking
      • 8.6.7.4. Strategic initiatives
    • 8.6.8. DyAnsys Inc.
      • 8.6.8.1. Company overview
      • 8.6.8.2. Financial performance
      • 8.6.8.3. Device benchmarking
      • 8.6.8.4. Strategic initiatives
    • 8.6.9. IMPETO MEDICAL
      • 8.6.9.1. Company overview
      • 8.6.9.2. Financial performance
      • 8.6.9.3. Device benchmarking
      • 8.6.9.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 North America diabetic neuropathy management market, By country, 2018 - 2030 (USD Million)
  • Table 4 North America diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 5 North America diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 6 North America diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 7 U.S diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 8 U.S diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 9 U.S diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 10 Canada diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 11 Canada diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 12 Canada diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 13 Mexico diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 14 Mexico diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 15 Mexico diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 16 Europe diabetic neuropathy management market, By country, 2018 - 2030 (USD Million)
  • Table 17 Europe diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 18 Europe diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 19 Europe diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 20 UK diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 21 UK diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 22 UK diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 23 Germany diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 24 Germany diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 25 Germany diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 26 France diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 27 France diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 28 France diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 29 Italy diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 30 Italy diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 31 Italy diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 32 Denmark diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 33 Denmark diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 34 Denmark diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 35 Sweden diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 36 Sweden diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 37 Sweden diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 38 Norway diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 39 Norway diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 40 Norway diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific diabetic neuropathy management market, By country, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 45 Japan diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 46 Japan diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 47 Japan diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 48 China diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 49 China diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 50 China diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 51 India diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 52 India diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 53 Australia diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 54 Australia diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 55 Australia diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 56 South Korea diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 57 South Korea diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 58 South Korea diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 59 Thailand diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 60 Thailand diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 61 Thailand diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 62 Latin America diabetic neuropathy management market, By Country, 2018 - 2030 (USD Million)
  • Table 63 Latin America diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 64 Latin America diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 65 Latin America diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 66 Brazil diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 67 Brazil diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 68 Brazil diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 69 Argentina diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 70 Argentina diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 71 Argentina diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 72 Middle East & Africa diabetic neuropathy management market, By country, 2018 - 2030 (USD Million)
  • Table 73 Middle East & Africa diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 74 Middle East & Africa diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 75 Middle East & Africa diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 76 South Africa diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 77 South Africa diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 78 South Africa diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 79 Saudi Arabia diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 80 Saudi Arabia diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 82 UAE diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 83 UAE diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 84 UAE diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 85 Kuwait diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 86 Kuwait diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 87 Kuwait diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value - chain - based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Diabetic neuropathy management market: market outlook
  • Fig. 14 Parent market outlook
  • Fig. 15 Related/ancillary market outlook
  • Fig. 16 Penetration and growth prospect mapping
  • Fig. 17 Industry value chain analysis
  • Fig. 18 Diabetic neuropathy management market driver impact
  • Fig. 19 Diabetic neuropathy management market restraint impact
  • Fig. 20 Diabetic neuropathy management market: Device movement analysis
  • Fig. 21 Diabetic neuropathy management market: Device outlook and key takeaways
  • Fig. 22 Electrical stimulation devices market estimates and forecast, 2018 - 2030
  • Fig. 23 Neuro stimulation devices market estimates and forecast, 2018 - 2030
  • Fig. 24 Nerve conduction testing devices market estimates and forecast, 2018 - 2030
  • Fig. 25 Other devices market estimates and forecast, 2018 - 2030
  • Fig. 26 Diabetic neuropathy management market: Application movement analysis
  • Fig. 27 Diabetic neuropathy management market: Application outlook and key takeaways
  • Fig. 28 Peripheral neuropathy market estimates and forecast, 2018 - 2030
  • Fig. 29 Autonomic neuropathy market estimates and forecast, 2018 - 2030
  • Fig. 30 Proximal neuropathy market estimates and forecast, 2018 - 2030
  • Fig. 31 Mononeuropathy market estimates and forecast, 2018 - 2030
  • Fig. 32 Hospitals market estimates and forecast, 2018 - 2030
  • Fig. 33 Home healthcare market estimates and forecast, 2018 - 2030
  • Fig. 34 Other end users market estimates and forecast, 2018 - 2030
  • Fig. 35 Diabetic neuropathy management market: End use movement analysis
  • Fig. 36 Diabetic neuropathy management market: End use outlook and key takeaways
  • Fig. 37 Hospitals market estimates and forecast, 2018 - 2030
  • Fig. 38 Home healthcare market estimates and forecast, 2018 - 2030
  • Fig. 39 Others end users market estimates and forecast, 2018 - 2030
  • Fig. 40 Global diabetic neuropathy management market: Regional movement analysis
  • Fig. 41 Global diabetic neuropathy management market: Regional outlook and key takeaways
  • Fig. 42 North America
  • Fig. 43 North America market estimates and forecasts, 2018 - 2030
  • Fig. 44 U.S.
  • Fig. 45 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 46 Canada
  • Fig. 47 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 48 Mexico
  • Fig. 49 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 50 Europe
  • Fig. 51 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 52 UK
  • Fig. 53 UK market estimates and forecasts, 2018 - 2030
  • Fig. 54 Germany
  • Fig. 55 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 56 France
  • Fig. 57 France market estimates and forecasts, 2018 - 2030
  • Fig. 58 Italy
  • Fig. 59 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 60 Spain
  • Fig. 61 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 62 Denmark
  • Fig. 63 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 64 Sweden
  • Fig. 65 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 66 Norway
  • Fig. 67 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 68 Asia Pacific
  • Fig. 69 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 70 China
  • Fig. 71 China market estimates and forecasts, 2018 - 2030
  • Fig. 72 Japan
  • Fig. 73 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 74 India
  • Fig. 75 India market estimates and forecasts, 2018 - 2030
  • Fig. 76 Thailand
  • Fig. 77 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 78 South Korea
  • Fig. 79 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 80 Australia
  • Fig. 81 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 82 Latin America
  • Fig. 83 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 84 Brazil
  • Fig. 85 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 86 Mexico
  • Fig. 87 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 88 Argentina
  • Fig. 89 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 90 Middle East and Africa
  • Fig. 91 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 92 South Africa
  • Fig. 93 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 94 Saudi Arabia
  • Fig. 95 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 96 UAE
  • Fig. 97 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 98 Kuwait
  • Fig. 99 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 100 Market share of key market players - Diabetic neuropathy management market